# US 6,719,977 B1 · Methods to potentiate cancer therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,719,977 B1
- Document ID: US6719977B1
- Status: Granted
- Kind: B1
- Application number: 09/601,919
- Filed: 2000-12-21
- Granted: 2004-04-13
- Earliest claimed: 1998-02-12
- Assignees: The General Hospital Corporation
- Inventors: Brian Seed; Rakesh K. Jain
- Web page: https://patentgrep.com/patent/US6719977B1

## CPC

- A61K 38/217: {IFN-gamma}
- A61K 38/2221: {Relaxins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods for potentiating the anti-cancer properties of an anti-cancer therapy in a mammal by administering with the therapy a compound (such as relaxin or γ-IFN) that has a tissue tensile modulus-reducing property, an ability to reduce the interstitial viscosity of the cancer, an ability to increase the hydraulic conductance of the cancer, or an ability to increase collagen turnover or decrease collagen formation at or near the cancer, where the therapy and the compound are administered at dosages which together are sufficient to destroy, slow, or arrest the cancer. Also disclosed is a method for treating cancer in a mammal involving the administration of relaxin and/or γ-IFN peptides and an anti-cancer therapy to the mammal, where the peptides and the therapy are administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.

## Claims

### Claim 1

A method of increasing the sensitivity of a mammalian solid tumor to an anti-cancer therapy, said method comprising administering to a mammal having a solid tumor relaxin and an anti-cancer therapy, said relaxin being administered at a dosage that increases the penetration of said anti-cancer therapy into said solid tumor.

### Claim 2 (depends on 1)

The method of claim 1, wherein said anti-cancer therapy comprises a biotherapeutic agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein said anti-cancer therapy comprises a chemotherapeutic agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein said relaxin is administered prior to the administration of said anti-cancer therapy.

### Claim 5 (depends on 1)

The method of claim 1, wherein said relaxin is administered simultaneously with the administration of said anti-cancer therapy.

### Claim 6 (depends on 1)

The method of claim 1, wherein said method further comprises administration of γ-interferon.

### Claim 7 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein said solid tumor is in a tissue selected from the group consisting of brain, kidney, liver, nasopharyngeal cavity, thyroid, skin, central nervous system, ovary, breast, prostate, colon, rectum, uterus, cervix, endometrium, lung, bladder, pancreas, and lymph node.